Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Company

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as Director of Operations in North America, to advise on regulatory affairs and provide technical and customer support.
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development

December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development

December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is...
Jonnie Yewdall

Former dairy farmer joins PBD Biotech’s fight against bovine TB

May 26, 2021
Jonnie Yewdall, a former dairy farmer, has been appointed Commercial Director at PBD Biotech. The company recently gained funding to take its Actiphage® blood test for bovine TB (bTB) and Johne’s Disease through the validation required for international industry acceptance.
Jonnie Yewdall

Former dairy farmer joins PBD Biotech’s fight against bovine TB

May 26, 2021
Jonnie Yewdall, a former dairy farmer, has been appointed Commercial Director at PBD Biotech. The company recently gained funding to...
Jonnie Yewdall

‘Game changing’ Actiphage bovine TB test gains funding for full validation

March 26, 2021
PBD Biotech has secured a £2.3m investment to take Actiphage through to validation by the World Organisation for Animal Health (OIE). Full validation will enable international adoption of this novel, patented, diagnostic for mycobacterial diseases, which include human tuberculosis and...
Jonnie Yewdall

‘Game changing’ Actiphage bovine TB test gains funding for full validation

March 26, 2021
PBD Biotech has secured a £2.3m investment to take Actiphage through to validation by the World Organisation for Animal Health...
Actiphage

PBD Biotech gains attention of East of England Investment Catalyst among other investors

October 7, 2019
TB in humans and animals is a huge global problem as there is a lack of rapid, accurate ways to detect the disease at an early stage. PBD Biotech has developed Actiphage®, a new sensitive test that can detect the...
Actiphage

PBD Biotech gains attention of East of England Investment Catalyst among other investors

October 7, 2019
TB in humans and animals is a huge global problem as there is a lack of rapid, accurate ways to...
Mark Hammond, PBD Biotech CEO

New CEO appointed to drive expansion

April 21, 2019
Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.
Mark Hammond, PBD Biotech CEO

New CEO appointed to drive expansion

April 21, 2019
Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company’s expansion.
Berwyn Clarke

PBD Biotech CEO announces his retirement

April 18, 2019
After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire as CEO to make time for other business interests. He will remain on the diagnostics company’s Board of Directors.
Berwyn Clarke

PBD Biotech CEO announces his retirement

April 18, 2019
After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire...
PBD Biotech at the Norfolk Business Awards

PBD Biotech recognised at Norfolk Business Awards

November 23, 2018
Local start-up PBD Biotech was announced as finalists for the Norfolk Business Awards’ “Breaking Boundaries” category and “Knowledge Pioneer of 2018” at a black-tie ceremony held at Norfolk Showground this week (22 November).
PBD Biotech at the Norfolk Business Awards

PBD Biotech recognised at Norfolk Business Awards

November 23, 2018
Local start-up PBD Biotech was announced as finalists for the Norfolk Business Awards’ “Breaking Boundaries” category and “Knowledge Pioneer of...
Mark Hammond, PBD Biotech CEO

PBD Biotech appoints new Commercial Director to drive expansion

November 1, 2018
PBD Biotech is delighted to announce the appointment of Mark Hammond as its new Commercial Director.
Mark Hammond, PBD Biotech CEO

PBD Biotech appoints new Commercial Director to drive expansion

November 1, 2018
PBD Biotech is delighted to announce the appointment of Mark Hammond as its new Commercial Director.
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More